At the end of 2017, the US FDA granted approval to GlaxoSmithKline for its shingles vaccine Shingrix, for adults age 50 years and older. Shingrix now stands to replace Zostavax (Merck), previously the only vaccine against herpes zoster and recommended for all adults age 60 years and older when it was approved in 2006.
Our 5-question quiz will test what you know about how the vaccines differ, patient selection for each, and about how shingles vaccine practice is going to shift to accommodate the newer of the two.
A 62-year-old man is in your office for vaccination with the new shingles vaccine Shingrix. He has asthma and is on every-other-day (QOD) dosing of 10 mg of prednisone and today has a cold.